TOP > 外国特許検索 > MEDICINE FOR PREVENTING OR TREATING TISSUE FIBROTIC DISEASES

MEDICINE FOR PREVENTING OR TREATING TISSUE FIBROTIC DISEASES

Foreign code F210010275
File No. 6405
Posted date 2021年1月8日
Country 世界知的所有権機関(WIPO)
International application number 2020JP007901
International publication number WO 2020175597
Date of international filing 令和2年2月27日(2020.2.27)
Date of international publication 令和2年9月3日(2020.9.3)
Priority data
  • 特願2019-035081 (2019.2.28) JP
Title MEDICINE FOR PREVENTING OR TREATING TISSUE FIBROTIC DISEASES
Abstract Provided is a medicinal composition to be used for preventing and/or treating tissue fibrotic diseases. The medicinal composition according to the present invention, which comprises a PI3Kδ inhibitor as an active ingredient, exhibits excellent effects on tissue fibrosis in various organs and, therefore, can prevent and/or treat tissue fibrotic diseases. As an example of the PI3Kδ inhibitor, [(3S)-3-({6-[2-(difluoromethyl)-1H-benzoimidazol-1-yl]-2-(morpholin-4-yl)pyrimidin-4-yl}amino)pyrrolidin-1-yl](oxan-4-yl)methanone or a salt thereof may be cited.
Outline of related art and contending technology Background Art
Tissue fibrosis is a bioadaptive response in the healing process of damaged tissue. Tissue fibrosis is mainly caused by abnormal growth of connective tissue in the tissue and excessive deposition of extracellular matrix such as collagen produced by fibroblasts.
Scleroderma is a systemic disease mainly composed of inflammatory and fibrotic changes, mainly composed of vascular disorders. (Non-Patent Document 1 and Non-Patent Document 2), wherein various cytokines are considered to be involved in fibrosis mainly in TGF-/ S and IL-6. In addition, although the skin fat layer is decreased in the skin of a scleroderma patient, in recent years, skin fat cell precursor cells control skin myofibroblasts and fibrosis in scleroderma (Non-Patent Document 3), Serum of a scleroderma patient inhibits differentiation of adipose-derived stem cells (Ad i pose-i nduced stem ce l l s) into adipocytes, Non-Patent Document 4) has been shown to reduce expression of perlipin (pe r i l i p i n) and adiponectin (ad i ponect i n) which are markers of adipocytes and change them like myofibroblasts, and it is believed that recovery of skin adipocytes may contribute to suppression of fibrosis. Adiponectin is one of cytokines produced by adipocytes, such as adipocyte differentiation promoting action, anti-inflammatory action, antifibrotic action (Non-Patent Document 1, Non-Patent Document 5, Non-Patent Document 7), Non-Patent Document 6), and Non-Patent Document 7), and Non-Patent Document 7), which also suggests the relationship between the scleroderma pathology and adipose tissue. Although the pathology of scleroderma has been elucidated, the therapeutic method
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • KYOTO UNIVERSITY
  • ASTELLAS PHARMA INC.
  • Inventor
  • ASHIDA, Noboru
  • NARUMIYA, Shuh
  • HIRAYAMA, Yoshitaka
  • ARAMORI, Ichiro
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
上記の特許・技術に関心のある方は、下記「問合せ先」まで直接お問い合わせください。

PAGE TOP

close
close
close
close
close
close